Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells

被引:58
作者
Liu, Daofeng [1 ,3 ]
Song, Liping [1 ,3 ]
Brawley, Vita S. [1 ,3 ]
Robison, Nathan [4 ,5 ]
Wei, Jie [1 ,3 ]
Gao, Xiuhua [1 ,3 ]
Tian, Gengwen [1 ,3 ]
Margol, Ashley [4 ,5 ]
Ahmed, Nabil [1 ,3 ]
Asgharzadeh, Shahab [4 ,5 ]
Metelitsa, Leonid S. [1 ,2 ,3 ]
机构
[1] Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA
[3] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
[4] Univ So Calif, Div Hematol Oncol, Dept Pediat, Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[5] Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA
基金
美国国家卫生研究院;
关键词
Medulloblastoma; NKT cells; CD1d; Cellular immunotherapy; Brain tumors; KILLER T-CELLS; SUBSETS; SUBGROUPS; THERAPY; LIGAND; LINE;
D O I
10.1016/j.clim.2013.06.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Medulloblastoma (MB) is the most common malignant brain tumor of childhood. Current therapies are toxic and not always curative that necessitates development of targeted immunotherapy. However, little is known about immunobiology of this tumor. In this study, we show that MB cells in 9 of 20 primary tumors express CD1d, an antigen-presenting molecule for Natural Killer T cells (NKTs). Quantitative RT-PCR analysis of 61 primary tumors revealed an elevated level of CD1d mRNA expression in a molecular subgroup characterized by an overactivation of Sonic Hedgehog (SHH) oncogene compared with Group 4. CD1d-positive MB cells cross-presented glycolipid antigens to activate NKT-cell cytotoxicity. Intracranial injection of NKTs resulted in regression of orthotopic MB xenografts in NOD/SCID mice. Importantly, the numbers and function of peripheral blood type-I NKTs were preserved in MB patients. Therefore, CD1d is expressed on tumor cells in a subset of MB patients and represents a novel target for immunotherapy. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:55 / 64
页数:10
相关论文
共 37 条
[1]   Regression of experimental medulloblastoma following transfer of HER2-specific T cells [J].
Ahmed, Nabil ;
Ratnayake, Maheshika ;
Savoldo, Barbara ;
Perlaky, Laszlo ;
Dotti, Gianpietro ;
Wels, Winfried S. ;
Bhattacharjee, Meenakshi B. ;
Gilbertson, Richard J. ;
Shine, H. David ;
Weiss, Heidi L. ;
Rooney, Cliona M. ;
Heslop, Helen E. ;
Gottschalk, Stephen .
CANCER RESEARCH, 2007, 67 (12) :5957-5964
[2]  
Ali Tahir SM, 2001, J IMMUNOL, V167, P4046
[3]   Distinct homeostatic requirements of CD4+ and CD4- subsets of Vα24-invariant natural killer T cells in humans [J].
Baev, DV ;
Peng, XH ;
Song, LP ;
Barnhart, JR ;
Crooks, GM ;
Weinberg, KI ;
Metelitsa, LS .
BLOOD, 2004, 104 (13) :4150-4156
[4]   Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals [J].
Brennan, Patrick J. ;
Tatituri, Raju V. V. ;
Brigl, Manfred ;
Kim, Edy Y. ;
Tuli, Amit ;
Sanderson, Joseph P. ;
Gadola, Stephan D. ;
Hsu, Fong-Fu ;
Besra, Gurdyal S. ;
Brenner, Michael B. .
NATURE IMMUNOLOGY, 2011, 12 (12) :1202-U97
[5]   Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome [J].
Cho, Yoon-Jae ;
Tsherniak, Aviad ;
Tamayo, Pablo ;
Santagata, Sandro ;
Ligon, Azra ;
Greulich, Heidi ;
Berhoukim, Rameen ;
Amani, Vladimir ;
Goumnerova, Liliana ;
Eberhart, Charles G. ;
Lau, Ching C. ;
Olson, James M. ;
Gilbertson, Richard J. ;
Gajjar, Amar ;
Delattre, Olivier ;
Kool, Marcel ;
Ligon, Keith ;
Meyerson, Matthew ;
Mesirov, Jill P. ;
Pomeroy, Scott L. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (11) :1424-1430
[6]   Differential antitumor immunity mediated by NKT cell subsets in vivo [J].
Crowe, NY ;
Coquet, JM ;
Berzins, SP ;
Kyparissoudis, K ;
Keating, R ;
Pellicci, DG ;
Hayakawa, Y ;
Godfrey, DI ;
Smyth, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (09) :1279-1288
[7]   Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion [J].
Dhodapkar, KM ;
Cirignano, B ;
Chamian, F ;
Zagzag, D ;
Miller, DC ;
Finlay, JL ;
Steinman, RM .
INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (06) :893-899
[8]   Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges [J].
Dhodapkar, Madhav V. .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 :796-807
[9]   A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma [J].
Dhodapkar, MV ;
Geller, MD ;
Chang, DH ;
Shimizu, K ;
Fujii, SI ;
Dhodapkar, KM ;
Krasovsky, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (12) :1667-1676
[10]   CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis [J].
Fais, F ;
Tenca, C ;
Cimino, G ;
Coletti, V ;
Zanardi, S ;
Bagnara, D ;
Saverino, D ;
Zarcone, D ;
De Rossi, G ;
Ciccone, E ;
Grossi, CE .
LEUKEMIA, 2005, 19 (04) :551-556